Volume 13, Number 1—January 2007
Questioning Aerosol Transmission of Influenza
We have reviewed the literature cited in Tellier’s Review of Aerosol Transmission of Influenza A Virus (1) and disagree that it supports the conclusions drawn regarding the importance of aerosols in natural influenza infection. In certain cited studies, researchers recovered viable virus from artificially generated aerosols; this is not evidence that aerosol transmission leads to natural human infection (2,3). By standard definitions, the rarity of long-range infections supports the conclusion that effective aerosol transmission is absent in the natural state (4) (www.cdc.gov/ncidod/dhqp/gl_isolation_hicpac.html). The superior efficacy of inhaled versus intranasal zanamivir is referenced as support for the idea that the lower respiratory tract is the preferred site of influenza infection; however, 1 study cited is insufficiently powered, and the other 2 do not compare the intranasal and inhaled routes (5–7). The major site of deposition of inhaled zanamivir is the oropharynx (77.6%), not the lungs (13.2%) (www.gsk.ca/en/products/prescription/relenza_pm.pdf). In another flawed study (8), study participants naturally infected with wild-type virus are compared with study participants experimentally infected with an attenuated strain.
In a review of such relevance, critical analysis of confounding factors is necessary. The Alaska Airlines outbreak (9) is presented as proof of airborne influenza transmission; however, droplet/contact transmission remains plausible because passenger movement was not restricted and the index patient was seated in high-traffic area. In the Livermore Hospital study (10), serious confounders such as bed arrangements, number of influenza exposures, patient mix, and ventilation were not accounted for.
We encourage readers of Teller’s article to review the relevant primary literature. We believe that the only reasonable conclusion that can be drawn at this time is that aerosol transmission does not play a major role in natural influenza epidemiology. Whether aerosols play any role in the transmission of influenza is a question demanding an answer; it is clear that we do not yet have that answer.
- Tellier R. Review of aerosol transmission of influenza A virus.Emerg Infect Dis. 2006;12:1657–62.
- Hemmes JH, Winkler K, Kool SM. Virus survival as a seasonal factor in influenza and poliomyelitis.Antonie Van Leeuwenhoek. 1962;28:221–33.
- Loosli C, Lemon H, Robertson O, Appel E. Experimental air-borne influenza infection. 1. Influence of humidity on survival of virus in air.Proc Soc Exp Biol Med. 1943;53:205–6.
- Health Canada. Routine practices and additional precautions for preventing the transmission of infection in health care: revision of isolation and precaution techniques. Canadian Communicable Disease Report. 1999;25(Suppl4).
- Calfee DP, Peng AW, Cass LM, Lobo M, Hayden FG. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection.Antimicrob Agents Chemother. 1999;43:1616–20.
- Kaiser L, Henry D, Flack NP, Keene O, Hayden FG. Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study.Clin Infect Dis. 2000;30:587–9.
- Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliot MJ, Hammond JM, Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group.N Engl J Med. 2000;343:1282–9.
- Little JW, Douglas RGJ, Hall WJ, Roth FK. Attenuated influenza produced by experimental intranasal inoculation.J Med Virol. 1979;3:177–88.
- Moser MR, Bender TR, Margolis HS, Noble GR, Kendal AP, Ritter DG. An outbreak of influenza on a commercial airliner.Am J Epidemiol. 1979;110:1–6.
- McLean RL. The effect of ultraviolet radiation upon the transmission of epidemic influenza in long-term hospital patients.Am Rev Respir Dis. 1961;83:36–8.
Suggested citation for this article: Lemieux C, Brankston G, Gitterman L, Hirji Z, Gardam M. Questioning aerosol transmission of influenza [letter]. Emerg Infect Dis [serial on the Internet]. 2007 Jan [date cited]. Available from http://wwwnc.cdc.gov/eid/article/13/1/06-1202
Please use the form below to submit correspondence to the authors or contact them at the following address:
Camille Lemieux, 200 Elizabeth St, NCSB 12C-1262, Toronto General Hospital, Toronto, Ontario, Canada, M5G 2C4;
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: June 28, 2010
- Page last updated: June 28, 2010
- Page last reviewed: June 28, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)